1. "2024"
Formats
  1. Journal Article (2329)
  2. Meeting Abstract (1694)
  3. Review (589)
  4. Editorial (305)
  5. Book Section (98)
  6. Correspondence (92)
  7. Guidelines (90)
  8. Research Letter (89)
  9. Miscellaneous (55)
  10. Conference Paper (33)
  11. Book Whole (3)
Groups
  1. Department of Medicine (2141)
  2. Solid Tumor Oncology Division (1382)
  3. Sloan Kettering Institute Postdocs (1038)
  4. Surgery (984)
  5. Graduate Medical Education (883)
  6. GSK Faculty (868)

More Groups

People
  1. Eileen O'Reilly (75)
  2. Saad Usmani (75)
  3. Edward Christopher Dee (70)
  4. Nadeem Abu-Rustum (70)
  5. Alice Wei (69)
  6. T Peter Kingham (68)

More People

Years
  1. 2024 (5377)
Publications
  1. Journal of Clinical Oncology (521)
  2. International Journal of Radiation Oncology, Biology, Physics (186)
  3. Blood (161)
  4. Annals of Oncology (147)
  5. Annals of Surgical Oncology (131)
  6. Laboratory Investigation (91)

More Publications

Publishers
  1. Elsevier Inc. (784)
  2. American Society of Clinical Oncology (580)
  3. Nature Publishing Group (384)
  4. Springer (357)
  5. Oxford University Press (347)
  6. Elsevier Science, Inc. (256)

More Publishers

Results (5377)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Update on GBM AGILE: A global, phase II/III adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma
    Meeting Abstract

    Weller, M.; Berry, D. A.; Blondin, N.; Buxton, M.; Colman, H.; de Groot, J. F.; de la Fuente, M.; Ducray, F.; Ellingson, B.; Gordon, G.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Encorafenib + cetuximab (EC) + FOLFIRI for BRAF V600E-mutant metastatic colorectal cancer (mCRC): Updated results from the BREAKWATER safety lead-in (SLI)
    Meeting Abstract

    Tabernero, J.; Yoshino, T.; Kim, T. W.; Yaeger, R.; Desai, J.; Wasan, H. S.; Van Cutsem, E.; Ciardiello, F.; Maughan, T.; Eng, C.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Concordance of PI3K-AKT pathway alterations between tumor and ctDNA in metastatic breast cancer
    Meeting Abstract

    Tsai, C.; An, J. A. R.; Cabel, L.; Brannon, A. R.; Moiso, E.; Gedvilaite, E.; Ahmed, M.; Loudon, L.; Weipert, C.; Chou, J.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Exposure-adjusted incidence rates (EAIRs) of adverse events (AEs) from the TROPION-Breast01 study of datopotamab deruxtecan (Dato-DXd) vs investigator's choice of chemotherapy (ICC) in patients (pts) with pretreated, inoperable/metastatic HR+/HER2e breast cancer (BC)
    Meeting Abstract

    Rugo, H. S.; Bardia, A.; Im, S. A.; Simon, S. P.; De Laurentiis, M.; Wang, S.; Martinez, N.; Borges, G. S.; Cescon, D.; Hattori, M.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Exploratory biomarker analysis of trastuzumab deruxtecan versus treatment of physician's choice in HER2-low, hormone receptorepositive metastatic breast cancer in DESTINY-Breast04
    Meeting Abstract

    Ueno, N. T.; Niikura, N.; Yamashita, T.; Jacot, W.; Cameron, D. A.; Tsurutani, J.; Sohn, J.; Tokunaga, E.; Losada, M. J. V.; Park, Y. H.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Treatment patterns and outcomes in HER2-low, HR+ metastatic breast cancer patients previously treated with endocrine therapy in the United States
    Meeting Abstract

    Modi, S.; Byng, D.; Zhang, S.; Xiong, Y.; Hunter, S.; Struebing, A.; Dunton, K.; Mbanya, Z.; Jacot, W.
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Ultra-sensitive ctDNA detection and monitoring in early breast cancer using PhasED-Seq
    Meeting Abstract

    Cabel, L.; An, J. A. R.; Kurtz, D.; Ross, D.; Dikoglu, E.; Chen, Y.; Murphy, K.; Szuhany, K.; Stowell, S. L.; Maloney, D.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Real-world evidence on risk of recurrence (ROR) in patients (pts) with node-negative (N0) and node-positive HR+/HER2-early breast cancer (EBC) from US electronic health records (EHR)
    Meeting Abstract

    Jhaveri, K.; Pegram, M.; Neven, P.; Curigliano, G.; Spring, L. M.; Gligorov, J.; Schlam, I.; Harbeck, N.; Juric, D.; Lim, E.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • A phase II study of nivolumab, ipilimumab plus bicalutamide in metastatic breast cancer
    Meeting Abstract

    Page, D. B.; Kaur, L.; Hong, E. C. C.; Su, A.; Moxon, N.; Mellinger, S.; Kelly, T.; Kelley, A.; Fredrich, N.; Seino, A.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Phase I/II dose escalation study evaluating first-in-class eIF4A inhibitor zotatifin in ER plus metastatic breast cancer
    Meeting Abstract

    Rosen, E.; Caswell-Jin, J.; Berz, D.; Mai, N.; Fulgar, G.; Densel, M.; Chiang, G.; Sperry, S.; Warner, D.; Meric-Bernstam, F.
    Annals of Oncology (2024)

    Fulltext@MSK | Save